HK1220966A1 - 盐酸苯达莫司汀固体形式 - Google Patents

盐酸苯达莫司汀固体形式 Download PDF

Info

Publication number
HK1220966A1
HK1220966A1 HK16108932.6A HK16108932A HK1220966A1 HK 1220966 A1 HK1220966 A1 HK 1220966A1 HK 16108932 A HK16108932 A HK 16108932A HK 1220966 A1 HK1220966 A1 HK 1220966A1
Authority
HK
Hong Kong
Prior art keywords
bendamustine hydrochloride
bendamustine
composition
hydrochloride
present
Prior art date
Application number
HK16108932.6A
Other languages
English (en)
Chinese (zh)
Inventor
伊安 庫珀 馬丁
伊安 库珀 马丁
勞倫特
D 库瓦西耶 劳伦特
庫瓦西耶
赫德尔斯顿 马克
赫德爾斯頓 馬克
E 麦基恩 罗伯特
羅伯特
麥基恩
Original Assignee
赛福伦公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1220966(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 赛福伦公司 filed Critical 赛福伦公司
Publication of HK1220966A1 publication Critical patent/HK1220966A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16108932.6A 2008-03-26 2016-07-26 盐酸苯达莫司汀固体形式 HK1220966A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3975208P 2008-03-26 2008-03-26
US61/039,752 2008-03-26

Publications (1)

Publication Number Publication Date
HK1220966A1 true HK1220966A1 (zh) 2017-05-19

Family

ID=41051023

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108932.6A HK1220966A1 (zh) 2008-03-26 2016-07-26 盐酸苯达莫司汀固体形式

Country Status (12)

Country Link
US (9) US20090264488A1 (enExample)
EP (2) EP3150197A1 (enExample)
JP (1) JP5536753B2 (enExample)
CN (3) CN103550159B (enExample)
AR (1) AR072777A1 (enExample)
CA (1) CA2718939A1 (enExample)
CL (1) CL2009000742A1 (enExample)
ES (1) ES2605205T3 (enExample)
HK (1) HK1220966A1 (enExample)
MX (2) MX2010010398A (enExample)
TW (1) TWI472515B (enExample)
WO (1) WO2009120386A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP5406197B2 (ja) * 2007-10-09 2014-02-05 ユーエス ワールドメッズ リミテッド ライアビリティ カンパニー ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010144675A1 (en) * 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
EP2516404A4 (en) 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JP6209446B2 (ja) 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
CN101948437B (zh) * 2010-06-28 2012-08-29 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀的精制方法
WO2012059935A1 (en) 2010-11-01 2012-05-10 Shilpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
WO2012103226A2 (en) * 2011-01-25 2012-08-02 Dr. Reddy's Laboratories Ltd. Bendamustine formulations
WO2012106117A1 (en) * 2011-01-31 2012-08-09 Cephalon, Inc. Methods for the preparation of bendamustine
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
CN102351799B (zh) * 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
EP2617716A1 (en) 2012-01-18 2013-07-24 Arevipharma GmbH Process for the preparation of bendamustine hydrochloride and related compounds
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
WO2013150020A1 (en) 2012-04-03 2013-10-10 Synthon Bv Process for making bendamustine
EP2656843B1 (en) 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2958554B1 (en) 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
US9315469B2 (en) 2013-03-14 2016-04-19 Johnson Matthey Public Limited Company Process for drying bendamustine hydrochloride monohydrate
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
WO2015138199A1 (en) 2014-03-13 2015-09-17 Voudouris Vasilios Bendamustine solid dispersions and continuous infusion
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
BR112017026586B1 (pt) * 2015-06-09 2021-11-03 Rebiotix, Inc. Composições de terapia de restauração de microbiota (mrt) e métodos de fabricação
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
AU2018346395A1 (en) 2017-10-05 2020-04-30 Mecox Curemed Co., Ltd. Oral bendamustine formulations
CN111093654B (zh) * 2017-11-07 2023-03-10 江苏恒瑞医药股份有限公司 一种盐酸苯达莫司汀的晶体及其制备方法
EA037673B1 (ru) * 2018-07-04 2021-04-29 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина
CA3108321A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023067188A1 (en) 2021-10-22 2023-04-27 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
DE159877C (enExample) *
DE293808C (enExample)
DE80967C (enExample)
DD80967A (enExample)
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
ATE65402T1 (de) 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
EP1005870B1 (en) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
NZ273752A (en) * 1993-10-27 1998-03-25 Upjohn Co Stabilised prostaglandin e1 lyophilisate using tertiary butanol and lactose carriers
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
JPH11511463A (ja) 1995-08-31 1999-10-05 スミスクライン・ビーチャム・コーポレイション インターロイキン変換酵素およびアポプトーシス
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CA2294247C (en) 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PT1104297E (pt) * 1998-07-09 2006-05-31 Cephalon Inc Composicoes para o tratamento da leucemia linfocitica cronica
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
EP1350793A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
WO2002080996A1 (de) * 2001-04-03 2002-10-17 Franz Herbst Medizinisches implantat und verfahren zu seiner herstellung
WO2003034944A1 (de) * 2001-10-15 2003-05-01 Hemoteq Gmbh Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
CA2478111C (en) 2002-03-22 2012-10-02 Ludwig Maximilians Universitat A cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
US20050176678A1 (en) 2002-05-09 2005-08-11 Roland Horres Compounds and method for coating surfaces in a haemocompatibe manner
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
AU2003286796A1 (en) 2002-10-31 2004-06-07 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7157551B2 (en) * 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
CA2585659A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
ES2350452T3 (es) 2004-11-22 2011-01-24 Venus Remedies Limited Formulación parenteral de aceclofenaco líquido no acuoso.
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
ES2365410T3 (es) 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITUD20070130A1 (it) 2007-07-23 2009-01-24 C M E Spa Sa Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
EP2424506A1 (en) 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine

Also Published As

Publication number Publication date
CN103550159B (zh) 2016-02-10
ES2605205T3 (es) 2017-03-13
AR072777A1 (es) 2010-09-22
US20160159748A1 (en) 2016-06-09
US8883836B2 (en) 2014-11-11
US20140187598A1 (en) 2014-07-03
US8445524B2 (en) 2013-05-21
US20090264488A1 (en) 2009-10-22
MX2010010398A (es) 2010-12-20
US20170071913A1 (en) 2017-03-16
EP2271315B1 (en) 2016-09-14
US20190015390A1 (en) 2019-01-17
MX339878B (es) 2016-06-15
US20150051258A1 (en) 2015-02-19
CL2009000742A1 (es) 2009-11-13
JP5536753B2 (ja) 2014-07-02
EP2271315A2 (en) 2011-01-12
TW200944508A (en) 2009-11-01
EP3150197A1 (en) 2017-04-05
US9533955B2 (en) 2017-01-03
US8669279B2 (en) 2014-03-11
CA2718939A1 (en) 2009-10-01
US20120071532A1 (en) 2012-03-22
WO2009120386A2 (en) 2009-10-01
WO2009120386A3 (en) 2009-12-03
US10039750B2 (en) 2018-08-07
US10517852B2 (en) 2019-12-31
US20130245086A1 (en) 2013-09-19
CN101980698A (zh) 2011-02-23
CN101980698B (zh) 2013-10-16
TWI472515B (zh) 2015-02-11
CN103550159A (zh) 2014-02-05
US20200323824A1 (en) 2020-10-15
JP2011515472A (ja) 2011-05-19
CN105693620A (zh) 2016-06-22

Similar Documents

Publication Publication Date Title
HK1220966A1 (zh) 盐酸苯达莫司汀固体形式
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
JP2012515210A (ja) ベンダムスチン遊離塩基の新規の形態
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
ES2815924T3 (es) Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
CN109843880B (zh) 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型
HK1151980B (en) Solid forms of bendamustine hydrochloride
HK1236383A1 (en) Solid forms of bendamustine hydrochlorid
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
RU2616976C1 (ru) Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof